
Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.

Your AI-Trained Oncology Knowledge Connection!


Caicun Zhou, MD, PhD, is the director of the Department of Oncology at Shanghai Pulmonary Hospital, and director of the Cancer Institute at Tongji University.